Pralsetinib companion diagnostic - Thermo Fisher Scientific
Alternative Names: BLU-667 companion diagnostic; ODxTT - Oncomine; Pralsetinib-companion diagnostic - Thermo Fisher Scientific; RET-kinase companion diagnostic - Thermo Fisher ScientificLatest Information Update: 23 Jul 2025
At a glance
- Originator Thermo Fisher Scientific
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Non-small cell lung cancer
- Discontinued Thyroid cancer
Most Recent Events
- 18 Jul 2025 Blueprint Medicines has been acquired by Sanofi
- 26 Sep 2024 Launched for Non-small cell lung cancer (Diagnosis, Metastatic disease) in USA (unspecified route) prior to September 2024 (Oncomine products page, September 2024)
- 12 Sep 2024 Discontinued - Clinical-Phase-Unknown for Thyroid cancer (Diagnosis) in USA (unspecified route)